NEW YORK — Patients with high-risk stage III melanoma who received ipilimumab after complete resection demonstrated prolonged RFS compared with patients who received placebo, according to phase 3 study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Conferences
Balance between benefits, harms key to limiting overdiagnosis in melanoma screening
Although overdiagnosis is common in cancer screening, it is not excessive if the benefits outweigh the harms, according to a presenter at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
PHP may increase survival in patients with liver metastases
Percutaneous hepatic perfusion increased hepatic progression free and overall survival rates in patients with liver metastases from melanoma vs. patients who underwent yttrium-90 therapy, according to data presented at the 2015 Society of Surgical Oncology Annual Cancer Symposium.
Fresh Insight on Ipilimumab’s Potential in the Adjuvant Melanoma Setting
Approved adjuvant therapy options for melanoma are currently limited, with the standard of care being interferon-alpha. However, new options are on the horizon, including ipilimumab (Yervoy), which is being studied for melanoma in the adjuvant setting as part of several trials.